Attention: This platform is in beta mode. Expect some changes and adjustments.

AI Market Mood: Stock Dashboard

CTMX


Fundamental

Company: CytomX Therapeutics Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: -
P/E: 4.82
EPS (ttm): 0.50
Insider Own: 33.99%
Shs Outstand: 157.54M
Perf Week: 0.84%
Market Cap: 376.53M
Forward P/E: -
EPS next Y: -0.41
Insider Trans: -0.30%
Shs Float: 103.99M
Perf Month: -15.25%
Enterprise Value: 304.79M
PEG: -
EPS next Q: -0.06
Inst Own: 31.71%
Short Float: 21.53%
Perf Quarter: 383.22%
Income: 41.60M
P/S: 2.55
EPS this Y: -124.50%
Inst Trans: 33.95%
Short Ratio: 4.29
Perf Half Y: 143.18%
Sales: 147.56M
P/B: 7.69
EPS next Y Percentage: -337.98%
ROA: 29.38%
Short Interest: 22.39M
Perf YTD: 132.04%
Book/sh: 0.31
P/C: 4.71
EPS next 5Y: -
ROE: -
52W High: 3.10 -22.78%
Perf Year: 82.44%
Cash/sh: 0.51
P/FCF: -
EPS past 3/5Y: - -
ROIC: 149.09%
52W Low: 0.40 497.50%
Perf 3Y: 94.31%
Dividend Est.: -
EV/EBITDA: 8.10
Sales past 3/5Y: 54.69% 19.16%
Gross Margin: 98.86%
Volatility W: 7.95%
Volatility M: 9.12%
Perf 5Y: -70.96%
Dividend TTM: -
EV/Sales: 2.07
EPS Y/Y TTM: 146.45%
Oper. Margin: 24.37%
ATR (14): 0.21
Perf 10Y: -
Dividend Ex-Date: -
Quick Ratio: 1.73
Sales Y/Y TTM: 23.81%
Profit Margin: 28.19%
RSI (14): 51.66
Recom: 1.50
Dividend Gr. 3/5Y: - -
Current Ratio: 1.73
EPS Q/Q: 61.71%
SMA20: 0.91%
Beta: 2.14
Target Price: 5.50
Payout: 0.00%
Debt/Eq: 0.33
Sales Q/Q: 22.80%
SMA50: 9.62%
Rel Volume: 0.16
Prev Close: 2.42
Employees: 121
LT Debt/Eq: 0.11
Earnings: May 12 BMO
SMA200: 96.51%
Avg Volume: 5.23M
Price: 2.39
IPO: Oct 08, 2015
Option/Short: Yes / Yes
EPS/Sales Surpr.: 116.35% 43.36%
Trades:
Volume: 815,283
Change: -1.24%

Technical:


Latest News:

CytomX stock slips on data for Amgen-partnered cancer drug | Seeking Alpha somewhat bearish
CTMX AMGN

Summary: CytomX Therapeutics (CTMX) shares sold off after reporting initial data from an early-stage trial for its experimental cancer therapy, CX-904, which showed partial responses in two pancreatic cancer patients.

Full article
2024-05-09T15:56:29Z
CytomX stock slips on data for Amgen-partnered cancer drug | Seeking Alpha neutral
CTMX AMGN

Summary: CytomX Therapeutics shares sold off after reporting initial data from an early-stage trial for its experimental cancer therapy, CX-904, which led to confirmed partial responses in two patients with pancreatic cancer.

Full article
2024-05-09T15:35:22Z
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update somewhat bullish
CTMX

Summary: CytomX Therapeutics, Inc. reported positive initial Phase 1a dose escalation data for CX-904, announced Phase 1 initiation for CX-2051 and CX-801, and achieved milestones under T-cell engaging bispecific collaboration. The company highlighted its leadership in developing PROBODY® therapeutics for cancer patients.

Full article
2024-05-09T11:53:48Z
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update somewhat bullish
CTMX

Summary: - CytomX Therapeutics, Inc. announced positive initial Phase 1a dose escalation data for CX-904 in solid tumors, initial data for CX-2051 expected in the first half of 2025, and initiation of Phase 1 study activities for CX-801 with Merck. The company reported upbeat progress and achieved milestones in their R&D partnerships and pipeline development. Financially, they reported increased revenue but decreased cash balance for the first quarter of 2024.

Full article
2024-05-08T20:24:22Z
Dow Jumps 200 Points Following Fed Decision; Pfizer Earnings Top Estimates very bullish
PFE CTMX

Summary: U.S. stocks traded higher with Dow Jones gaining over 200 points. Pfizer reported better-than-expected first-quarter financial results. CytomX Therapeutics, Inc. shares surged 148%.

Full article
2024-05-01T18:54:29Z